juvenil
neuron
ceroid
lipofuscinosi
jncl
childhood
neurodegen
diseas
earlyonset
sever
central
vision
loss
affect
children
develop
seizur
cn
degener
accompani
sever
motor
cognit
deficit
cure
jncl
patient
usual
die
second
third
decad
life
studi
independ
line
induc
pluripot
stem
cell
ipsc
gener
two
patient
molecularli
confirm
mutat
gene
mutat
jncl
clinicalgrad
adenoassoci
adenoviru
serotyp
carri
fulllength
code
sequenc
human
gener
us
food
drug
administrationregist
cgmp
facil
efficaci
restor
fulllength
transcript
protein
patientspecif
fibroblast
ipscderiv
retin
neuron
inject
subretin
space
wildtyp
mice
purifi
show
evid
retin
toxic
studi
provid
proofofprincipl
initi
clinic
trial
use
aavmedi
gene
augment
treatment
children
retin
degener
introduct
neuron
ceroid
lipofuscinos
ncl
group
progress
neurodegen
disord
affect
children
young
adult
date
differ
genet
subtyp
ncl
age
onset
vari
infantil
adult
describ
autosom
recess
juvenil
form
jncl
commonli
known
batten
diseas
preval
present
roughli
everi
live
birth
worldwid
although
differ
mutat
gene
ceroid
lipofuscinosi
neuron
report
caus
jncl
approxim
patient
harbor
genom
delet
induc
frameshift
insert
prematur
stop
codon
least
one
allel
encod
acid
hydrophob
protein
name
traffick
express
lysosom
membran
mutat
lead
buildup
autofluoresc
lipofuscinlik
deposit
within
lysosom
affect
neuron
cell
jncl
often
refer
lysosom
storag
disord
jncl
present
rapidli
progress
retin
degener
typic
manifest
year
age
ophthalmoscop
find
includ
bull
eye
maculopathi
optic
nerv
pallor
attenu
arteriol
peripher
retin
granular
within
year
diagnosi
patient
usual
experi
profound
vision
loss
due
primarili
death
lightsens
photoreceptor
cell
outer
neural
retina
ensu
decad
extens
death
cn
neuron
lead
onset
seizur
difficulti
commun
problem
walk
ultim
death
second
third
decad
life
us
food
drug
administr
fda
approv
treatment
current
exist
fatal
diseas
fact
jncl
recess
diseas
caus
variat
gene
express
retina
rais
possibl
lessen
risk
recurr
diseas
affect
famili
combin
genet
counsel
preimplant
genet
test
prevent
neural
cell
death
diseas
progress
via
gene
addit
adenoassoci
viru
aav
base
gene
augment
treatment
retin
degen
disord
leber
congenit
amaurosi
highli
success
singl
subretin
inject
serotyp
shown
well
toler
suffici
induc
prolong
protein
express
human
likewis
improv
visual
acuiti
pupillari
light
reflex
visual
field
ambulatori
vision
detect
earli
week
postinject
close
correl
area
retina
receiv
treatment
advers
immun
respons
extraocular
spread
detect
encourag
result
combin
fact
vector
shown
transduc
cone
photoreceptor
cell
inner
retin
neuron
suggest
vector
could
ideal
deliveri
fulllength
mean
mitig
diseas
progress
loss
vision
jncl
advanc
induc
pluripot
stem
cell
ipsc
technolog
made
possibl
gener
patientspecif
retin
photoreceptor
cell
vitro
cell
use
evalu
pathophysiolog
newli
identifi
genet
variant
determin
efficaci
novel
genebas
therapeut
case
rare
diseas
jncl
good
anim
model
retin
degener
lack
abil
gener
patientspecif
photoreceptor
cell
allow
us
test
whether
aavbas
gene
augment
capabl
restor
wildtyp
transcript
protein
without
induc
overexpress
toxic
patient
treatment
intend
combin
approach
vivo
toxic
studi
wildtyp
anim
one
could
significantli
reduc
time
gene
discoveri
first
therapeut
trial
human
studi
gener
independ
ipsc
line
two
patient
molecularli
confirm
jncl
patient
del
patient
clinicalgrad
viru
carri
fulllength
gener
fdaregist
facil
use
current
good
manufactur
practic
cgmp
deliveri
fulllength
via
adenoassoci
viral
vector
restor
fulllength
transcript
protein
patientspecif
fibroblast
ipscderiv
retin
cell
vitro
inject
wildtyp
mice
purifi
viru
demonstr
complet
lack
retin
toxic
studi
provid
proofofprincipl
singleey
gene
augment
trial
children
jncl
studi
approv
institut
review
board
univers
iowa
project
approv
adher
tenet
set
forth
declar
helsinki
patient
refer
number
correspond
molecularli
confirm
mutat
follow
patient
patient
del
skin
biopsi
mm
obtain
either
nonsunexpos
upper
arm
lower
abdomen
minc
iowa
xenofre
ie
free
animalderiv
product
biopsi
medium
ixmedia
patientspecif
dermal
fibroblast
plate
well
cultur
dish
ixmedia
twentyfour
hour
transduct
medium
switch
xenofre
serumfre
ixmedia
next
day
cell
transduc
nonintegr
sendai
viral
vector
drive
express
cmyc
multipl
infect
moi
cytotuneip
reprogram
kit
cat
invitrogen
thermo
fisher
scientif
waltham
viral
transduct
medium
serumfre
ixmedia
plu
lm
rock
inhibitor
cat
emd
millipor
billerica
transduct
medium
remov
hr
later
replac
daili
serumfre
ixmedia
five
day
transduct
fibroblast
passag
onto
fresh
xenofre
human
coat
cultur
dish
cat
corn
life
scienc
tewksburi
fed
fresh
serumfre
ixmedia
plu
revitacel
cat
life
technologiesthermo
fisher
scientif
day
medium
transit
xenofre
human
essenti
cat
life
technolog
thermo
fisher
scientif
use
equal
part
essenti
serumfre
ixmedia
day
day
cultur
fed
daili
fresh
essenti
day
cultur
transit
human
essenti
ipsc
mainten
medium
cat
life
technologiesthermo
fisher
scientif
fed
daili
ipsc
coloni
reach
mm
diamet
manual
isol
passag
fresh
cultur
plate
clonal
expand
human
essenti
medium
expans
cell
analyz
pluripot
ie
express
endogen
pluripot
factor
via
rtpcr
loss
transgen
express
ie
lack
detect
express
cmyc
use
qpcrbase
scorecard
assay
rtpcr
total
rna
isol
rneasi
mini
kit
cat
qiagen
germantown
md
accord
manufactur
instruct
one
hundr
nanogram
rna
templat
amplifi
onestep
rtpcr
use
superscript
iii
onestep
rtpcr
system
cat
life
technolog
thermo
fisher
scientif
primer
hybrid
human
transcript
list
tabl
clone
transgen
cassett
plasmid
carri
member
parvoviru
famili
nonpathogen
helperdepend
singlestrand
dna
viru
express
cassett
contain
minim
cytomegaloviru
cmv
promot
cmv
immediateearli
enhanc
normal
human
fulllength
code
sequenc
cdna
contain
code
sequenc
human
idtdna
technolog
coralvil
ia
clone
pfbaavmcsbghpa
plasmid
backbon
provid
univers
iowa
viral
vector
core
facil
plasmid
backbon
follow
characterist
contain
ampicillin
gentamicin
resist
gene
select
growth
contain
bacteri
origin
replic
puc
contain
invert
termin
repeat
final
plasmid
sequenc
confirm
via
bidirect
sanger
sequenc
packag
patientspecif
ipsc
control
ipsc
differenti
day
retin
precursor
cell
infect
hr
viral
titer
moi
sixteen
hour
postinfect
cell
wash
fresh
differenti
medium
fed
everi
day
day
ten
day
postinfect
cell
harvest
western
blot
analysi
procedur
also
perform
patientspecif
fibroblast
western
blot
perform
describ
previous
briefli
cell
treat
trypsinedta
life
technolog
homogen
lysi
buffer
mm
trishcl
ph
mm
nacl
mm
cacl
triton
nan
sigmaaldrich
centrifug
supernat
protein
concentr
determin
via
bicinchonin
acid
bca
assay
accord
manufactur
instruct
pierc
rockford
il
forti
microgram
subject
sdspage
trisglycin
transfer
polyvinyliden
difluorid
pvdf
probe
dilut
cat
abcam
cambridg
uk
alexa
fluorconjug
secondari
antibodi
life
technolog
use
blot
visual
fluoresc
versadoc
imag
system
biorad
hercul
ca
antigapdh
dehydrogenas
dilut
cat
abcam
antibodi
use
intern
load
control
clinicalgrad
cgmp
aav
product
manufactur
current
good
manufactur
practic
cgmp
steven
w
dezii
translat
vision
research
facil
dtvrf
within
stephen
wynn
institut
vision
research
univers
iowa
facil
contain
independ
higheffici
particul
air
hepa
filter
equip
room
iso
intern
organ
standard
class
class
materi
storag
handl
room
two
iso
class
class
gown
area
two
iso
class
class
process
room
unclassifi
servic
chase
dedic
access
equip
facil
mainten
two
process
room
equip
custom
biospherix
xvivo
close
incub
system
design
exceed
iso
class
class
cleanli
requir
ensur
minim
biolog
contamin
throughout
standard
oper
procedur
provid
absolut
optim
condit
longterm
cultur
cell
defin
atmospher
condit
manufactur
use
character
human
master
cell
line
packag
vector
particl
cell
transfect
set
construct
encod
normal
human
contain
express
cassett
flank
itr
aav
packag
plasmid
contain
rep
cap
sequenc
helper
virusderiv
sequenc
phelper
contain
gene
adenoviru
serotyp
requir
packag
plasmid
sequenc
confirm
via
bidirect
sequenc
packag
dtvrf
cell
taken
qualifi
master
cell
bank
dtvrf
plate
expand
multilay
tissu
cultur
flask
product
batch
scale
flask
reach
confluenc
cell
simultan
transfect
phelper
purifi
follow
step
perform
cultur
passag
centrifug
remov
cell
cultur
reagent
low
molecular
weight
impur
cell
lyse
releas
intracellular
vector
nucleas
digest
perform
remov
nucleic
acid
impur
cell
debri
remov
lysat
via
filtrat
use
filter
densiti
gradient
ultracentrifug
perform
separ
empti
capsid
major
impur
vector
product
affin
chromatographi
perform
use
kta
pure
chromatographi
system
ge
healthcar
life
scienc
pittsburgh
pa
purifi
vector
viral
particl
subsequ
concentr
via
buffer
exchang
work
concentr
formul
inject
buffer
mm
nacl
plu
mm
na
po
trisodium
phosphat
water
inject
ph
filter
filter
vial
label
purifi
assess
rtpcr
viral
contamin
human
simian
bovin
porcin
origin
briefli
total
rna
isol
rneasi
mini
kit
qiagen
accord
manufactur
instruct
one
microgram
rna
revers
transcrib
use
superscript
anim
procedur
approv
univers
iowa
anim
care
use
committe
ten
mice
jackson
laboratori
bar
harbor
anesthet
ketaminexylazin
mixtur
inject
via
subretin
space
describ
previous
month
age
right
eye
receiv
purifi
concentr
clinicalgrad
cgmp
vector
genom
vg
volum
left
eye
receiv
dose
serv
contralater
control
mice
sacrif
histolog
week
inject
rtpcr
vehicleand
eye
ten
mice
jackson
laboratori
anesthet
ketaminexylazin
mixtur
inject
via
subretin
space
describ
previous
month
age
right
eye
receiv
purifi
concentr
clinicalgrad
cgmp
vg
volum
left
eye
receiv
steril
inject
buffer
mm
nacl
plu
mm
na
po
water
inject
ph
serv
contralater
vehicl
control
mice
sacrif
rtpcr
human
express
week
postinject
briefli
eye
enucl
posterior
eyecup
dissect
anterior
chamber
whole
retina
harvest
rna
isol
total
rna
isol
rneasi
mini
kit
cat
qiagen
accord
manufactur
instruct
one
hundr
nanogram
rna
templat
use
gener
cdna
use
superscript
vilo
cdna
synthesi
kit
cat
thermo
fisher
scientif
two
hundr
nanogram
cdna
amplifi
primer
hybrid
human
list
tabl
mous
eye
enucl
fix
paraformaldehyd
pfa
hr
embed
paraffin
paraffinembed
eye
section
deparaffin
counterstain
hematoxylin
eosin
accord
standard
procedur
slide
mask
whether
eye
slide
imag
evo
xl
core
microscop
cat
life
technologiesthermo
fisher
scientif
assess
retina
retin
toxic
retin
toxic
assess
measur
thick
outer
nuclear
layer
use
softwar
nation
institut
health
bethesda
ten
random
imag
one
differ
section
obtain
person
mask
treatment
group
eye
total
imag
per
group
outer
nuclear
layer
thick
measur
three
differ
area
imag
averag
treatment
group
assess
uninject
wildtyp
retina
outer
nuclear
layer
thick
measur
section
center
globe
eye
differ
mice
pair
twotail
student
test
perform
determin
signific
use
prism
graphpad
softwar
la
jolla
ca
p
consid
statist
signific
test
efficaci
virusmedi
correct
diseas
vitro
first
gener
patientderiv
ipsc
ipscderiv
neuron
retin
precursor
cell
skin
biopsi
acquir
two
patient
molecularli
confirm
mutat
patient
compound
heterozygot
patient
homozygot
del
wicel
research
institut
madison
wi
human
ipsc
line
use
nondiseas
control
fibroblast
isol
cultur
reprogram
induc
pluripot
stem
cell
ipsc
via
viral
transduct
transcript
factor
cmyc
previous
describ
approxim
week
transduct
dens
pack
coloni
cell
high
nucleustocytoplasm
ratio
fig
isol
clonal
expand
passag
express
pluripot
transcript
cmyc
nanog
confirm
via
rtpcr
fig
pluripot
assess
newli
avail
taqman
human
pluripot
stem
cell
scorecard
panel
assay
use
realtim
pcr
compar
transcript
express
level
requir
selfrenew
ectoderm
mesoderm
endoderm
format
line
interest
undifferenti
ipsc
refer
gene
set
pairwis
comparison
c
valu
gene
test
show
pluripot
transcript
similar
one
anoth
demonstr
scatter
plot
correl
coeffici
fig
vs
p
vs
p
vs
p
taken
togeth
data
show
success
gener
two
independ
ipsc
line
patient
mutat
human
control
ipsc
line
success
gener
patientspecif
ipsc
differenti
line
develop
ipscderiv
retin
cell
test
abil
adenoassoci
viral
particl
carri
wildtyp
fulllength
tabl
restor
express
protein
experi
use
twodimension
differenti
protocol
previous
demonstr
develop
patientspecif
retin
cell
fig
inset
aav
chose
studi
serotyp
aav
vector
design
cmv
promot
drive
gene
express
fig
aav
vector
serotyp
success
use
clinic
human
gene
augment
trial
treat
leber
congenit
amaurosi
initi
test
abil
vector
drive
transcript
transduc
patient
fibroblast
perform
rtpcr
use
primer
specif
human
littl
transcript
detect
fibroblast
deriv
either
patient
jncl
transduct
fig
abl
drive
restor
robust
express
transcript
cell
patient
fig
test
efficaci
restor
fulllength
protein
patientspecif
retin
neuron
differenti
patient
ipsc
day
time
point
neuron
rosett
clearli
visibl
differenti
cultur
fig
inset
assess
protein
level
produc
immunoblot
use
human
antibodi
robustli
express
whole
retin
protein
lysat
isol
human
donor
eye
expect
fig
h
ret
neuron
unaffect
control
patient
day
postdifferenti
express
wherea
undifferenti
ipsc
fig
ipsc
vs
restor
fulllength
protein
retin
neuron
deriv
patient
compar
uninfect
differenti
neuron
fig
data
demonstr
success
clone
packag
aav
vector
drive
vector
efficaci
restor
fulllength
transcript
protein
patientspecif
neural
progenitor
cell
demonstr
success
restor
fulllength
transcript
protein
patientderiv
cell
next
sought
produc
vector
clinicalgrad
manner
suitabl
use
clinic
trial
children
jncl
achiev
produc
cgmp
condit
onsit
fdaregist
cgmp
facil
facil
exce
iso
class
class
cleanli
requir
ensur
minim
biolog
contamin
throughout
standard
oper
procedur
provid
optim
condit
longterm
cultur
cell
defin
atmospher
condit
manufactur
character
human
master
cell
line
cell
transfect
transgen
cassett
plasmid
packag
plasmid
contain
rep
cap
sequenc
plasmid
carri
helper
virusderiv
sequenc
phelper
contain
gene
adenoviru
serotyp
purifi
cultur
passag
centrifug
remov
cell
cultur
reagent
low
molecular
weight
impur
lyse
digest
releas
intracellular
vector
remov
nucleic
acid
impur
cellular
debri
remov
lysat
via
filtrat
follow
densiti
gradient
ultracentrifug
separ
empti
capsid
major
impur
vector
product
final
affin
chromatographi
perform
purifi
vector
subsequ
concentr
via
buffer
exchang
demonstr
puriti
perform
seri
rtpcr
assess
presenc
virus
vector
contamin
demonstr
fig
complet
devoid
viral
dna
human
fig
simian
fig
bovin
fig
porcin
origin
fig
also
lack
express
virus
specifi
code
feder
regul
fig
demonstr
subretin
inject
transduc
neural
retina
inject
wildtyp
mice
either
steril
inject
buffer
n
vg
n
week
postinject
rtpcr
use
primer
specif
human
show
robust
express
transcript
retina
compar
vehicleinject
control
fig
highli
pure
concentr
vector
hand
next
ask
whether
deliveri
viral
titer
exceed
would
like
test
human
would
toxic
inject
wildtyp
murin
retina
inject
wildtyp
mice
either
vg
n
right
eye
vg
n
left
eye
assess
retin
histolog
month
postinject
uninject
wildtyp
eye
use
addit
control
ensur
green
fluoresc
protein
gfp
induc
retin
toxic
fig
vectorinduc
toxic
assess
measur
compar
mean
thick
outer
nuclear
layer
treatment
group
mean
outer
nuclear
layer
thick
differ
eye
fig
p
likewis
hematoxylinand
eosinstain
section
morpholog
ident
uninject
fig
fig
eye
fig
togeth
data
demonstr
product
highli
pure
potent
safe
cgmpcompliant
clinicalgrad
vector
studi
describ
gener
clinicalgrad
cgmpcompliant
patientspecif
ipsc
two
individu
retin
degener
demonstr
use
cell
test
efficaci
clinicalgrad
aavmedi
gene
augment
strategi
furthermor
show
nontox
mous
retina
deliv
vivo
propos
data
provid
proofofconcept
design
initi
clinic
trial
children
jncl
diseas
nonintegr
success
use
clinic
gene
transfer
vehicl
treat
human
retin
degen
diseas
establish
safe
well
toler
restrict
eye
subretin
deliveri
exampl
carri
gene
reproduc
demonstr
safe
benefici
treatment
leber
congenit
amaurosi
safeti
efficaci
profil
coupl
fact
vector
capabl
carri
fulllength
shown
capabl
transduc
cone
photoreceptor
inner
retin
neuron
make
logic
choic
treatment
jncl
retina
highli
special
extens
brain
deriv
neural
ectoderm
like
cerebr
cortex
organ
lamin
structur
consist
divers
mixtur
neuron
glia
similar
neural
retina
cerebr
cortex
suggest
success
gene
augmentationbas
approach
eye
could
serv
proofofprincipl
similar
treatment
brain
vivo
anim
studi
assess
efficaci
safeti
aavmedi
gene
deliveri
brain
demonstr
two
form
ncl
infantil
ncl
caus
mutat
gene
late
infantil
ncl
caus
mutat
gene
aav
deliveri
brain
demonstr
mice
rat
nonhuman
primat
canin
likewis
one
group
demonstr
efficaci
aavmedi
deliveri
murin
eye
show
cn
deliveri
amelior
function
deficit
mous
importantli
treatment
children
late
infantil
ncl
administ
throughout
cn
slow
diseas
progress
studi
laid
groundwork
similar
treatment
children
diseas
aavmedi
therapi
found
safe
effect
eye
deliveri
brain
would
next
logic
step
although
observ
efficaci
eye
children
would
great
achiev
would
significantli
reduc
suffer
diseas
blind
one
problem
face
patient
jncl
develop
treatment
could
use
slow
prevent
cognit
declin
onset
seizur
loss
motor
function
associ
jncl
ultim
goal
unlik
gene
transcrib
solubl
enzym
encod
intracellular
protein
local
membran
lysosom
unfortun
mean
compar
ncl
effect
treat
transduc
rel
small
number
cell
reli
secret
gene
product
induc
widespread
rescu
effect
gene
augment
effect
like
extens
cn
transduct
necessari
although
transduct
cone
photoreceptor
cell
inner
retin
neuron
may
suffici
prevent
vision
loss
like
serotyp
demonstr
significantli
better
transduc
cn
neuron
requir
even
treat
entir
cn
one
would
need
deliv
larg
quantiti
viral
vector
mean
perhap
repeat
intrathec
inject
whether
patient
could
toler
treatment
whether
could
amelior
condit
suffici
make
worthwhil
complet
unknown
present
time
altern
approach
would
identifi
system
activ
compound
perhap
even
oral
deliver
would
act
slow
halt
diseas
progress
jncl
demonstr
autoimmun
compon
sever
group
attempt
use
variou
immunosuppress
agent
purpos
instanc
seehaf
colleagu
demonstr
immunomodulatori
compound
mycophenol
mofetil
trade
name
cellcept
given
mice
decreas
immunoglobulin
g
deposit
promot
cell
surviv
improv
motor
function
phase
clinic
trial
design
evalu
use
compound
children
jncl
current
underway
clinic
trial
promis
find
immunosuppress
agent
less
ideal
decreas
patient
abil
respond
infect
increas
chanc
develop
cancer
caus
injuri
vital
organ
although
anim
model
diseas
valuabl
test
therapeut
efficaci
largescal
screen
compound
may
capabl
alter
diseas
progress
requir
vitro
model
patientspecif
ipsc
recapitul
key
diseas
phenotyp
autofluoresc
lysosom
storag
granul
mani
patient
jncl
retin
diseas
progress
beyond
point
gene
replac
therapi
would
benefici
patient
transplant
ipscderiv
photoreceptor
precursor
may
eventu
abl
restor
vision
autolog
cell
replac
therapi
one
would
first
need
correct
mutat
prevent
newli
transplant
cell
suffer
fate
origin
one
particularli
import
jncl
earli
onset
aggress
photoreceptor
death
fortun
advanc
genom
edit
allow
highli
specif
correct
diseasecaus
allel
patientspecif
stem
cell
jncl
inherit
autosom
recess
fashion
correct
either
patient
diseasecaus
allel
suffici
advantag
common
mutat
genom
delet
occur
approxim
patient
exampl
two
patient
investig
studi
harbor
mutat
one
heterozyg
homozyg
design
strategi
correct
variant
would
allow
product
healthi
immunolog
match
photoreceptor
precursor
cell
use
cell
replac
therapi
conclus
demonstr
develop
clinicalgrad
vector
capabl
restor
fulllength
transcript
protein
retin
cell
deriv
two
patient
jncl
furthermor
safe
eye
wildtyp
mice
display
complet
lack
vectorinduc
overexpress
toxic
studi
provid
preclin
data
use
treat
retin
degen
blind
caus
mutat
gene
author
thank
patient
particip
research
studi
work
support
grant
stephen
wynn
foundat
elmer
sylvia
sramek
charit
foundat
nation
institut
health
research
prevent
blind
foundat
fight
blind
compet
financi
interest
exist
